Risk Factors and Management of Hepatitis B Virus Reactivation in Patients With Hematological Disorders
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2018Yazar
Akay, Fatih ErkanTan, Berfin
Güldağ, Mahmut Alper
Çifcibaşı, Hilal Sena
Elmacı, Kubilay
Ümit, Elif Gülsüm
Üst veri
Tüm öğe kaydını gösterÖzet
Aims: The aim of this study is to evaluate hepatitis B virus serological status and to categorize the risks of our treatmentmodalities in patients with both benign and malignant hematological disorders.Methods: This was a retrospective study of 552 patients who were admitted to the Trakya University Hospital Hematologyunit between 01.01.2017 and 31.12.2017. All data regarding the diagnosis, treatment and HBV serologicalstatus were collected from patient files. Data were analyzed with IBM SPSS V.20 using descriptive statistical analysis.Results: Hepatitis B surface antigen was positive in 45 (8.2%) patients, antibody to the hepatitis B surface antigenwas positive in 279 (50.5%) patients and antibody to the hepatitis B core antigen was positive in 247 (44.7%) patients.According to these results, 32 patients were found to be vaccinated for hepatitis B virus. Reactivation was observed in4 (0.7%) patients who have been hepatitis B surface antigen positive and have received adequate duration of antiviralprophylaxis with tenofovir. These 4 patients have received monoclonal antibody for immunosuppressive treatment.Conclusion: To conclude, although the rate of hepatitis B surface antigen reactivation is quite low, as many patientsas possible should be vaccinated to reduce the costs of antiviral treatments and monitorization. If there is notime to vaccinate, patients should be categorized according to guidelines by their hepatitis B surface antigen serologicalstatus and by the planned immunosuppressive treatments.
Cilt
5Sayı
1Bağlantı
https://dergipark.org.tr/tr/pub/tmsj/issue/36656/420829https://dergipark.org.tr/tr/download/article-file/467615
http://dspace.trakya.edu.tr/xmlui/handle/trakya/6293